Key Highlights

  • Price $4.54 (-1.7% today) · Mkt cap $363 million · 92% adjusted upside potential · Next catalyst: key study enrollment by end of July
  • JPMorgan reduced Lexeo’s target price from $12 to $9, a 25% cut, but maintained an Overweight rating
  • Company finalized trial protocol for SUNRISE-FA 2 and statistical plan for 2028 Biologics License Application
  • Shares down 52.8% year-to-date but up 3.9% over the past month

Lexeo Therapeutics (NASDAQ: LXEO) remains one of the best stocks under $10 with potential to triple, even after JPMorgan slashed its price target by a quarter. The clinical-stage biotech, trading near $4.54, still offers over 92% upside to the revised $9 target, reflecting confidence in its genetic medicine pipeline despite a steep year-to-date decline.

JPMorgan Trims Target but Keeps Overweight

JPMorgan lowered its price target for Lexeo from $12 to $9 on June 25, marking a 25% reduction. The firm maintained its Overweight rating, signaling that the stock’s long-term potential outweighs near-term volatility. Analysts noted the adjustment reflects evolving expectations around the company’s lead candidate, LX2006, for Friedreich’s ataxia cardiomyopathy, rather than a loss of conviction in the program itself.

The company recently finalized the protocol for its SUNRISE-FA 2 trial on June 15, a critical step toward initiating a key study. Lexeo also completed the statistical analysis plan for its Biologics License Application, targeting FDA approval under the 2028 pathway. Chief Medical Officer Narinder Bhalla indicated enrollment for the first patient in the key trial is expected by the end of this month.

The Numbers Behind the Move

Lexeo’s shares fell 1.7% to $4.54 in recent trading, extending its year-to-date loss to 52.8%. The stock has shown signs of stabilization, however, with a 3.9% gain over the past month. Its market capitalization stands at $363 million, and the 52-week range spans from $3.60 to $10.99.

The 92% upside potential to JPMorgan’s $9 target suggests the stock is undervalued relative to its pipeline progress. While the target cut may reflect cautious optimism, the firm’s Overweight rating underscores that the risk-reward balance remains favorable for investors willing to tolerate clinical-stage volatility.

Why It Matters Now

Lexeo’s focus on genetic medicines for rare diseases positions it in a high-risk, high-reward segment of biotech. Friedreich’s ataxia, a progressive neurodegenerative disorder, has no approved treatments, making LX2006 a potential breakthrough if clinical trials succeed. The company’s push to enroll patients in its key study by the end of July could serve as a near-term catalyst, offering clarity on timelines and regulatory expectations.

The stock’s sharp decline this year contrasts with its recent momentum, suggesting investors are reassessing the balance between pipeline potential and execution risks.

What to Watch Next

The immediate focus is on Lexeo’s ability to enroll the first patient in its key study by the end of July. Success in this phase could validate the company’s timeline for a Biologics License Application and reignite investor interest. Meanwhile, any updates on trial design or regulatory feedback will be critical in shaping sentiment ahead of the 2028 approval target.

Based on the company’s June 15 and June 25 disclosures.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.